Table 2.

MDSCs isolated from the spleens of both cancer patients and those with benign cysts suppress T cell activation and proliferation

Patient tumor type	Stage	% Suppressiona
		CD15+	CD14+
Benign p. cyst	n/a	55.0	n/a
Benign p. cyst	n/a	89.7	n/a
Benign p. cyst	n/a	47.8	17.5
P. adenocarcinoma	I	40.6	n/a
P. adenocarcinoma	I	13.9	n/a
P. neuroendocrine tumor	I	21.8	28.9
P. neuroendocrine tumor	I	33.3	9.75
P. neuroendocrine tumor	Ib	40.6	n/a
P. neuroendocrine tumor	IIb	8.63	n/a
P. neuroendocrine tumor	IV	33.3	9.75
P. neuroendocrine tumor	IV	85.9	n/a
Ovarian cancer	IV	21.8	28.9
Melanoma	IV	35.6	41.1
Colon adenocarcinoma	IIIb	47.3	n/a

^aCFSE-labeled T cells were stimulated with allogenic dendritic cells in the presence of HLA-DR+ control cells or MDSCs. After 4 days, cells were stained with antibodies specific for CD3, CD8, and CD25 and the frequency of divided (CFSE low) CDS T cells was determined by flow cytometry. The percent suppression of proliferation was determined for each sample relative to HLA-DR+ cells